Menu
Search
Wednesday, January 14, 2026

Creating liberating content

Email us
Subscribe
Menu
Search

AstraZeneca to Acquire EsoBiotec...

By engineering immune cells directly within the patient’s body, EsoBiotec is eliminating the barriers of traditional cell therapies and unlocking new possibilities for oncology and immune-mediated diseases.

Signal12 gears up for...

BOSTON, March 18, 2025: Signal12, a clinical-stage ophthalmic pharmaceutical company has announced the...
News

AstraZeneca to Acquire EsoBiotec for $1B. Aims to advance cell therapy ambition

By engineering immune cells directly within the patient’s body, EsoBiotec is eliminating the barriers of traditional cell therapies and unlocking new possibilities for oncology and immune-mediated diseases.
Press Releases

Signal12 gears up for phase 3 clinical trials for ocular graft-versus-host disease

BOSTON, March 18, 2025: Signal12, a clinical-stage ophthalmic pharmaceutical company has announced the alignment of its Phase 3 clinical trial strategy for Pro-ocular™ with...

Enjoy exclusive access to our content

Get an online subscription and you can unlock any article you come across, getting instant emails when our site updates, too.

Subscribe today ⟶

Editors Choice

News

AstraZeneca to Acquire EsoBiotec for $1B. Aims to advance cell therapy ambition

By engineering immune cells directly within the patient’s body, EsoBiotec is eliminating the barriers of traditional cell therapies and unlocking new possibilities for oncology and immune-mediated diseases.
Press Releases

Signal12 gears up for phase 3 clinical trials for ocular graft-versus-host disease

BOSTON, March 18, 2025: Signal12, a clinical-stage ophthalmic pharmaceutical company has announced the alignment of its Phase 3 clinical trial strategy for Pro-ocular™ with...

Interviews

Partners Content

Enjoy exclusive access to our content

Get an online subscription and you can unlock any article you come across, getting instant emails when our site updates, too.

Subscribe today ⟶

News From Events

News

AstraZeneca to Acquire EsoBiotec for $1B. Aims to advance cell therapy ambition

By engineering immune cells directly within the patient’s body, EsoBiotec is eliminating the barriers of traditional cell therapies and unlocking new possibilities for oncology and immune-mediated diseases.
Press Releases

Signal12 gears up for phase 3 clinical trials for ocular graft-versus-host disease

BOSTON, March 18, 2025: Signal12, a clinical-stage ophthalmic pharmaceutical company has announced the alignment of its Phase 3 clinical trial strategy for Pro-ocular™ with...

Global News

Medical News

Most Popular

All

Become part of the community

Subscribe today
Latest News

AstraZeneca to Acquire EsoBiotec for $1B. Aims to advance cell therapy ambition

By engineering immune cells directly within the patient’s body, EsoBiotec is eliminating the barriers of traditional cell therapies and unlocking new possibilities for oncology and immune-mediated diseases.

Signal12 gears up for phase 3 clinical trials for ocular graft-versus-host disease

BOSTON, March 18, 2025: Signal12, a clinical-stage ophthalmic pharmaceutical company has announced the alignment of its Phase 3 clinical trial strategy for Pro-ocular™ with the U.S. Food and Drug Administration (FDA). The novel drop-free therapy is poised to revolutionize...

Create a website from scratch

With Newspaper Theme you can drag and drop elements onto a page and customize them to perfection. Try it out today and create the perfect site to express yourself!

Buy Now ⟶

AstraZeneca to Acquire EsoBiotec for $1B. Aims to advance cell therapy ambition

By engineering immune cells directly within the patient’s body, EsoBiotec is eliminating the barriers of traditional cell therapies and unlocking new possibilities for oncology and immune-mediated diseases.

Signal12 gears up for phase 3 clinical trials for ocular graft-versus-host disease

BOSTON, March 18, 2025: Signal12, a clinical-stage ophthalmic pharmaceutical company has announced the alignment of its Phase 3 clinical trial strategy for Pro-ocular™ with the U.S. Food and Drug Administration (FDA). The novel drop-free therapy is poised to revolutionize...
spot_img

Create a website from scratch

With Newspaper Theme you can drag and drop elements onto a page and customize them to perfection. Try it out today and create the perfect site to express yourself!

Buy Now ⟶

AstraZeneca to Acquire EsoBiotec for $1B. Aims to advance cell therapy ambition

By engineering immune cells directly within the patient’s body, EsoBiotec is eliminating the barriers of traditional cell therapies and unlocking new possibilities for oncology and immune-mediated diseases.

Signal12 gears up for phase 3 clinical trials for ocular graft-versus-host disease

BOSTON, March 18, 2025: Signal12, a clinical-stage ophthalmic pharmaceutical company has announced the alignment of its Phase 3 clinical trial strategy for Pro-ocular™ with the U.S. Food and Drug Administration (FDA). The novel drop-free therapy is poised to revolutionize...

Enjoy exclusive access to our content

Get an online subscription and you can unlock any article you come across, getting instant emails when our site updates, too.

Subscribe today ⟶

Amsonia Menu

Categories to explore

BahrainBiopharmaBiotechCorporateEventsFeaturesGlobal

Contribute as an author

Who we are